HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Monika Szczepanowski Selected Research

Lymphoma (Lymphomas)

1/2022PARP14 is a novel target in STAT6 mutant follicular lymphoma.
1/2020Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma.
12/2018Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma.
11/2016Alterations of microRNA and microRNA-regulated messenger RNA expression in germinal center B-cell lymphomas determined by integrative sequencing analysis.
11/2015DNA methylome analysis in Burkitt and follicular lymphomas identifies differentially methylated regions linked to somatic mutation and transcriptional control.
9/2015MINCR is a MYC-induced lncRNA able to modulate MYC's transcriptional network in Burkitt lymphoma cells.
6/2015Multiplex ligation-dependent probe amplification validates LOH6q analyses and enhances insight into chromosome 6q aberrations in pediatric T-cell lymphoblastic leukemia and lymphoma.
1/2015Epstein-Barr virus-negative diffuse large B-cell lymphoma hosts intra- and peritumoral B-cells with activated Epstein-Barr virus.
7/2013Composite lymphoma of nodular lymphocyte-predominant and classical Hodgkin lymphoma-Epstein-Barr virus association suggests divergent pathogenesis despite clonal relatedness.
2/2013High resolution copy number analysis of IRF4 translocation-positive diffuse large B-cell and follicular lymphomas.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Monika Szczepanowski Research Topics

Disease

16Lymphoma (Lymphomas)
01/2022 - 06/2006
10B-Cell Lymphoma (Lymphoma, B Cell)
11/2017 - 06/2006
8Neoplasms (Cancer)
01/2022 - 12/2009
6Burkitt Lymphoma (Burkitt's Lymphoma)
01/2019 - 09/2015
5Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
01/2020 - 08/2013
4Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/2023 - 08/2010
4Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
12/2020 - 07/2016
2B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
10/2022 - 08/2010
2Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
07/2015 - 08/2010
2Hodgkin Disease (Hodgkin's Disease)
07/2013 - 10/2007
2Genetic Translocation (Chromosomal Translocation)
07/2011 - 08/2010
1Lymphoid Leukemia
01/2022
1Hematologic Neoplasms (Hematological Malignancy)
01/2022
1Residual Neoplasm
01/2022
1Basal Cell Carcinoma (Rodent Ulcer)
12/2020
1Leiomyosarcoma
12/2020
1Inflammation (Inflammations)
10/2018
1Non-Hodgkin Lymphoma (Lymphosarcoma)
08/2017
1Germ Cell and Embryonal Neoplasms (Germ Cell Tumor)
10/2012
1Microsatellite Instability
10/2012
1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)
05/2011
1Disease Progression
02/2011
1Chromosome Aberrations (Chromosome Abnormalities)
08/2010
1Lymphadenitis (Adenitis)
12/2009
1Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma)
10/2007

Drug/Important Bio-Agent (IBA)

7ParaffinIBA
12/2020 - 02/2013
7Formaldehyde (Formol)FDA Link
12/2020 - 02/2013
6RNA (Ribonucleic Acid)IBA
01/2022 - 06/2006
4Proteins (Proteins, Gene)FDA Link
12/2020 - 10/2007
3Immunoglobulins (Immunoglobulin)IBA
01/2023 - 07/2011
3DNA (Deoxyribonucleic Acid)IBA
01/2016 - 02/2013
2carboxyl radical (COO-)IBA
12/2020 - 08/2017
2CytokinesIBA
01/2020 - 10/2018
2Biomarkers (Surrogate Marker)IBA
07/2016 - 10/2012
1Interleukin-4 (Interleukin 4)IBA
01/2022
1Spironolactone (Aldactone)FDA LinkGeneric
12/2020
1AntigensIBA
01/2020
1cathepsin SIBA
01/2020
1Complement System Proteins (Complement)IBA
01/2019
1AutoantigensIBA
12/2018
1EpitopesIBA
12/2018
1neurabinIBA
12/2018
1ExotoxinsIBA
12/2018
1ChemokinesIBA
10/2018
1Proto-Oncogene Proteins c-bcl-2 (Proto Oncogene Proteins c bcl 2)IBA
08/2017
1Pyruvic Acid (Pyruvate)IBA
01/2017
1human MIRN142 microRNAIBA
11/2016
1Messenger RNA (mRNA)IBA
11/2016
1MicroRNAs (MicroRNA)IBA
11/2016
1human MIRN376C microRNAIBA
11/2016
1Phosphates (Orthophosphate)IBA
11/2015
1hydrogen sulfite (bisulfite)IBA
11/2015
1SphingosineIBA
11/2015
1Long Noncoding RNAIBA
09/2015
1Transcription Factors (Transcription Factor)IBA
09/2015
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
09/2015
1Rituximab (Mabthera)FDA Link
09/2015
1Carrier Proteins (Binding Protein)IBA
09/2015
1Doxorubicin (Adriamycin)FDA LinkGeneric
09/2015
1Prednisone (Sone)FDA LinkGeneric
09/2015
1Vincristine (Oncovin)FDA LinkGeneric
09/2015
1Cyclin D1IBA
07/2015
1Membrane Proteins (Integral Membrane Proteins)IBA
07/2013
1T-Cell Antigen Receptors (T-Cell Receptor)IBA
05/2011
1Telomerase (Telomerase Reverse Transcriptase)IBA
08/2010
1oncofetal fibronectinIBA
12/2009
1TenascinIBA
12/2009
1Protein Isoforms (Isoforms)IBA
12/2009
1Coloring Agents (Dyes)IBA
12/2009
1AntibodiesIBA
12/2009
1Guanine Nucleotide Dissociation Inhibitors (GDIs)IBA
10/2007

Therapy/Procedure

3Therapeutics
10/2022 - 02/2011
2Drug Therapy (Chemotherapy)
01/2022 - 02/2011
1Precision Medicine
01/2022
1Aftercare (After-Treatment)
01/2019
1Ligation
06/2015
1Lasers (Laser)
07/2013